Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Improving pediatric drug efforts

This article was originally published in The Tan Sheet

Executive Summary

FDA will launch an internal panel of experts to provide advice on pediatric studies and exclusivities, Commissioner Andrew von Eschenbach says Oct. 25. With the new Pediatric Review Committee looking over all written requests for pediatric studies, the agency expects to define more precisely the studies it wants industry to perform. The PeRC also will analyze FDA's past performance in implementing provisions of the Pediatric Research Equity Act concerning assessments of a drug's efficacy and safety in the pediatric population. It will be composed of representatives from FDA's centers for drug and for biologics evaluation and research and the commissioner's office and will meet weekly...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS101045

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel